Trade LCTX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Lineage Cell Therapeutics, Inc. (LCTX) is trading at US$1.03, up 0.00% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$273.14M. Over the past 52 weeks, LCTX has traded between US$1.00 and US$2.09. On Syfe you can trade LCTX with $0 commission and add it to your watchlist.
| Previous close | US$1.03 |
|---|---|
| Market cap | US$273.14M |
| 52-week range | US$1.00 – US$2.09 |
| Volume | 3.21M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Year: 1992
--Canaccord Genuity Initiates Coverage on Lineage Cell Therapeutics With Buy Rating, $9 PT
Apr 28, 11:38 AM · MT Newswires
B. Riley Raises Price Target on Lineage Cell Therapeutics to $4 From $3, Keeps Buy Rating
Mar 25, 11:50 AM · MT Newswires
Lineage Cell Therapeutics, Inc. (LCTX) stock is trading at US$1.03, 0.00% from the previous close of US$1.03.
The market cap for Lineage Cell Therapeutics, Inc. (LCTX) stock is approximately US$273.14M.
The 52-week high for Lineage Cell Therapeutics, Inc. (LCTX) stock is US$2.09.
The 52-week low for Lineage Cell Therapeutics, Inc. (LCTX) stock is US$1.00.
Lineage Cell Therapeutics, Inc. (LCTX) does not currently pay a dividend.
Stay on top of LCTX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
